Secukinumab Prescribing Patterns in Patients with Psoriatic Arthritis in the United States: Data from Secukinumab Service Request Forms

Abstract

s201were from all regions of the United States (Northeast, 19.3%; North Central, 15.7%; South, 44.7%; West, 16.1%; Puerto Rico/Virgin Islands, 0.4%); approximately 60% of patients were female and the mean (SD) age was 53.6 (12.0) years. Overall, 6.1% of patients were biologic naive, 41.9% received ≥ 1 prior biologic therapy, and 52.0% had missing information about prior biologic use. Among patients with prior biologic use, 38.6% had 1 reported biologic efficacy failure, 33.8% had 2 efficacy failures, and 27.7% had ≥ 3 efficacy failures; the most commonly reported biologic efficacy failures were adalimumab (67.4%) and etanercept (59.1%). For both initial and maintenance dosing, approximately half of patients were prescribed secukinumab 300 mg (51.1% and 51.6%, respectively). ConClusions: In this analysis of SRFs filled by patients with PsA and their health care providers, approximately half of patients were prescribed secukinumab 300 mg for both initial and maintenance dosing. These results provide early insights into the prescribing patterns of secukinumab for PsA in a US real-world setting. Future research is needed to better understand how clinical characteristics and treatment history may affect secukinumab usage in US patients with PsA.